Handelsbanken Fonder’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$30.9M Buy
79,811
+5,772
+8% +$2.14M 0.09% 197
2026
Q1
$21.7M Buy
74,039
+1,402
+2% +$461K 0.07% 222
2025
Q4
$25.5M Sell
72,637
-1,799
-2% -$608K 0.08% 223
2025
Q3
$24.1M Buy
74,436
+1,297
+2% +$403K 0.08% 229
2025
Q2
$28.4M Buy
73,139
+10,253
+16% +$4.12M 0.1% 189
2025
Q1
$27.4M Sell
62,886
-570
-0.9% -$229K 0.11% 177
2024
Q4
$23.4M Sell
63,456
-11,864
-16% -$4.96M 0.09% 205
2024
Q3
$39.2M Buy
75,320
+2,987
+4% +$1.6M 0.15% 132
2024
Q2
$39.2M Sell
72,333
-10,270
-12% -$5.43M 0.17% 117
2024
Q1
$42.8M Buy
82,603
+4,831
+6% +$2.4M 0.18% 119
2023
Q4
$36.7M Buy
77,772
+161
+0.2% +$74.4K 0.18% 127
2023
Q3
$33.8M Sell
77,611
-292
-0.4% -$132K 0.19% 122
2023
Q2
$34.6M Buy
77,903
+1,133
+1% +$523K 0.19% 124
2023
Q1
$35.3M Buy
76,770
+4,073
+6% +$1.94M 0.2% 113
2022
Q4
$37.3M Buy
72,697
+4,965
+7% +$2.52M 0.23% 106
2022
Q3
$30.8M Buy
67,732
+2,903
+4% +$1.39M 0.21% 119
2022
Q2
$31.3M Buy
64,829
+2,393
+4% +$1.18M 0.2% 118
2022
Q1
$30.7M Buy
62,436
+1,550
+3% +$709K 0.17% 135
2021
Q4
$28.2M Buy
60,886
+461
+0.8% +$194K 0.14% 166
2021
Q3
$22.5M Buy
60,425
+1,274
+2% +$484K 0.12% 188
2021
Q2
$22.6M Sell
59,151
-2,362
-4% -$903K 0.12% 185
2021
Q1
$22.1M Buy
61,513
+2,460
+4% +$791K 0.13% 167
2020
Q4
$19M Buy
59,053
+1,100
+2% +$338K 0.12% 186
2020
Q3
$15.6M Buy
57,953
+200
+0.3% +$53.8K 0.11% 187
2020
Q2
$15.2M Buy
+57,753
New +$15.4M 0.13% 155
2018
Q1
Sell
-5,000
Closed -$1.13M 204
2017
Q4
$1.13M Buy
+5,000
New +$1.06M 0.02% 164
2017
Q2
Sell
-48,000
Closed -$7.94M 172
2017
Q1
$7.94M Buy
48,000
+43,500
+967% +$6.92M 0.22% 94
2016
Q4
$647K Hold
4,500
0.02% 153
2016
Q3
$564K Sell
4,500
-1,893
-30% -$244K 0.02% 157
2016
Q2
$840K Sell
6,393
-74,000
-92% -$10.1M 0.03% 129
2016
Q1
$11.2M Sell
80,393
-39,600
-33% -$5.29M 0.48% 71
2015
Q4
$16.7M Buy
+119,993
New +$16.5M 0.32% 97

Other funds holding ELV

Handelsbanken Fonder's ELV Position: Q2 2026 in Review

Handelsbanken Fonder increased its Elevance Health (ELV) stake by 7.8% in Q2 2026, buying an estimated $2.14M and bringing the position to 79,811 shares worth $30.9M. The position accounts for 0.09% of the portfolio, ranked #197.

Handelsbanken Fonder first reported a position in ELV in Q4 2015 and has held it in 32 quarters since. The position peaked at $42.8M in Q1 2024. 1,602 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Handelsbanken Fonder held 79,811 shares of Elevance Health worth $30.9M as of Q2 2026.
  • Handelsbanken Fonder bought 5,772 Elevance Health shares in Q2 2026, an estimated $2.14M.
  • Elevance Health made up 0.09% of Handelsbanken Fonder's portfolio in Q2 2026, its #197 holding.
  • Handelsbanken Fonder first reported a position in Elevance Health in Q4 2015 and has held it in 32 quarters since.
  • Handelsbanken Fonder's Elevance Health position peaked at $42.8M in Q1 2024.
  • 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.